⏳ Fetching live dividend data...
Home › Calculator › GLYC Dividend Calculator 2026
GlycoMimetics, Inc. · NASDAQ
Price: $15.71 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in GLYC → $26633.77M in 10 years · $2,202,590,775.95/month
GlycoMimetics, Inc. operates as a clinical-stage pharmaceutical company, specializing in the research and development of groundbreaking glycomimetic therapies. Its core mission is to address critical unmet medical requirements arising from various diseases within the United States. A key focus of their pipeline is uproleselan, an E-selectin inhibitor. This drug is being advanced for acute myeloid leukemia (AML), both as a combination therapy with chemotherapy and is currently undergoing a Phase 3 clinical trial for patients experiencing relapsed or refractory forms of AML. Additionally, the company is developing GMI-1359, a compound designed to target both E-selectin and a specific chemokine receptor. This candidate is aimed at treating cancers that affect the bone and bone marrow, encompassing a range of solid tumors. Beyond these lead programs, GlycoMimetics is also progressing other experimental treatments, such as GMI-1687, an E-selectin antagonist intended for the management of vaso-occlusive crises, and a series of galectin-3 antagonists, which are compounds that interact with carbohydrate-binding proteins. In terms of collaborations, GlycoMimetics maintains a cooperative research and development pact with the National Cancer Institute. The company has also entered into a licensing and collaboration deal with Apollomics (Hong Kong) Limited for the global advancement and commercialization of uproleselan and GMI-1687. Founded in 2003, GlycoMimetics, Inc. conducts its operations from its corporate headquarters in Rockville, Maryland.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GLYC position with:
Real after-tax yield depends on where you live and how you hold GLYC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 12.73% | 9.93% | $1,273 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 10.82% | 8.02% | $1,082 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 10.18% | 7.38% | $1,018 / yr |
| 🇬🇧 UK ISA | 0% | 12.73% | 9.93% | $1,273 / yr |
| 🇬🇧 UK Taxable | 8.75% | 11.62% | 8.82% | $1,162 / yr |
| 🇨🇦 TFSA | 0% | 12.73% | 9.93% | $1,273 / yr |
| 🇨🇦 CA Taxable | 25% | 9.55% | 6.75% | $955 / yr |
| 🇦🇺 Super (pension) | 15% | 10.82% | 8.02% | $1,082 / yr |
| 🇦🇺 AU Taxable | 30% | 8.91% | 6.11% | $891 / yr |
| 🇩🇪 DE Taxable | 26.375% | 9.37% | 6.57% | $937 / yr |
| 🇫🇷 FR Taxable | 30% | 8.91% | 6.11% | $891 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
GLYC pays quarterly — 4 times per year. Next ex-div: TBD.
How GLYC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GLYC sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GLYC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
GlycoMimetics, Inc. (GLYC) is currently trading at $15.71, trading near its 52-week low. The current dividend yield is 12.73% based on an annual payout of $2.00 per share.
GlycoMimetics, Inc. (GLYC) is a healthcare stock currently trading at $15.71 with a dividend yield of 12.73%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever